Aura revolutionizes biologic stability analysis, enabling simple protein and non-protein aggregate identification in formulation development and analytical testing

 

BURLINGAME, CA – June 25, 2020 – Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest aggregate and particle identification system, called Aura™.

Aura is the next generation of the Horizon®, Halo Labs’ popular Backgrounded Membrane Imaging (BMI) platform. With as little as 5 µL and a linear range of over 3×106 particles/mL, BMI can count, size, and image aggregates and particles in the subvisible range (>1 μm). The Aura instrument now adds protein/non-protein identification using Fluorescence Membrane Microscopy (FMM) and is the only subvisible particle analyzer on the market to have 100% sample efficiency. An optional second fluorescence channel gives customers the ability to also detect lipids and other drug and process-specific particles.

“Aura is going to completely revolutionize biologic stability analysis,” said Rick Gordon, Vice President of Sales at Halo Labs. “Finally, there’s an easy way for our customers to identify if large aggregates in their samples are protein or non-protein without having to resort to slow and cumbersome methods like Raman and FTIR. Particle identification is critical to formulation development and analytical testing in all biologics because it defines the path that needs to be taken to mitigate problems. I’m extremely happy to be able to deliver this solution to our customers”.

“The wide adoption of our technology by every major biopharmaceutical company has given us a unique opportunity to listen to many customer voices,” said Robert Wicke, CEO of Halo Labs. “There is so much that this technology can offer and we are very excited to watch the Aura platform change the way stability and quality are analyzed in biologics.”

 

About Halo Labs

Halo Labs in Burlingame, CA, is a venture-backed scientific instrumentation and consumable company that commercializes high throughput biopharmaceutical formulation and quality control tools for subvisible particle analysis using state-of-the-art custom optics and image processing techniques. Researchers around the globe depend on Halo Labs for unprecedented insights into aggregates and subvisible particles present in their drug products via optical imaging on membranes.  Halo Labs has been the recipient of many prestigious awards and has received many research grants from agencies including DARPA, FDA, NSF, NIST, and NIH. For more information, visit www.halolabs.com.

 

 

 

Contact

Rick Gordon

Vice President of Sales

Phone:  215.253.5777

rick.gordon@halolabs.com

###

Aura is a trademark of Halo Labs in the United States.  All rights reserved.

 

BURLINGAME, Calif., April 6, 2020 /PRNewswire/ — Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has closed a $12M Series B1 financing round led by Research Corporation Technologies (RCT).  The funding will be used for expanding Halo Labs’ world-wide Sales presence and the continued development of the company’s next-generation product portfolio.  In addition, Halo Labs is actively looking at acquiring complementary technologies and companies to expand into the analytical particle space.

The Horizon® instrument performs high throughput subvisible particle (SVP) analysis using volumes as low as 25 µL, ensuring samples can be saved for other analyses or for replicates.  It has a 96-well membrane plate that allows several parameters to be tested in a short amount of time without dilution or sample preparation.

“Horizon is crucial at every stage of biologic drug formulation,” said Chad Souvignier, Vice President of RCT.  “In early stages, it can reveal SVP formation missed by other techniques such as light obscuration and flow imaging.  In later stages, it can differentiate proteins from extrinsic particles such as glass and plastic. And given the experience of the Halo Labs management team in product development and Sales, we are eager to find other technologies that we can help bring to market.” Additional backers included BroadOak Capital Partners, BioAdvance, top level industry executive Paul McEwan, and other current employees.

“The success of Horizon, especially in the Gene Therapy field, provides confirmation that next-generation product development is critical. There is so much more this technology can provide in a variety of markets,” said Robert Wicke, CEO of Halo Labs.  “One of our latest customers, the US FDA, will be using the product to help understand the risks for patients on drug product manufacturing. This is a further indication that Horizon is the product of choice for particle analysis in the subvisible range.

Halo Labs serves customers from the drug discovery phase through formulations and bioprocessing, empowering researchers to learn more about the stability and quality of their biological drugs faster and with more accuracy.  Over the years, Halo Labs has been the recipient of many prestigious awards and has received many research grants from agencies including DARPA, FDA, NSF, NIST, and NIH.

About Halo Labs
Halo Labs in Burlingame, CA, is a venture-backed scientific instrumentation and consumable company that commercializes high throughput biopharmaceutical formulation and quality control tools for subvisible particle analysis using state-of-the-art custom optics and image processing techniques. Researchers around the globe depend on Halo Labs for unprecedented insights into subvisible particles present in their processes via optical imaging on membranes.  For more information, visit www.halolabs.com.

About RCT
Research Corporation Technologies (RCT) in Tucson, Ariz., is a technology investment and management company that provides early-stage funding and development for promising biomedical companies and technologies. RCT focuses on investing in technology that originated in universities and research institutions worldwide. http://www.rctech.com

CONTACT:
Renee Tobias
Halo Labs
Director, Marketing
Phone:  215.253.5777
Renee.Tobias@halolabs.com

Horizon is a registered trademark of Halo Labs in the United States.  All rights reserved.

Company announces headquarters and all operations moving to San Francisco Bay Area

BURLINGAME, CALIFORNIA, May 1, 2019 — Halo Labs, a life science instrumentation company developing tools for subvisible particle analysis for biopharmaceuticals, today announced the opening of its new headquarters in Burlingame, California. The new headquarters will house sales, marketing, engineering, and manufacturing personnel and serve as the company’s primary Horizon® instrument production facility.  With the opening of its new headquarters, Halo Labs also announced its previous headquarters in Philadelphia will be closing by the end of fiscal Q2 2019.

Launched in 2017, the Horizon® system can analyze subvisible and visible particles, including protein aggregates.  Using the latest optics and innovative algorithms, it utilizes a plate-based approach that enables high-throughput (up to 96 samples/run), low-volume (as little as 25 µL/sample) particle analysis in a wide-range of pharmaceutical samples from pre-formulation through quality control for a wide range of therapeutics including biologics, vaccines, lipid nanoparticles, and small molecules.

“I am very excited to have Halo Labs right here at home in the San Francisco Bay Area.  The talent pool here is fantastic and our growth will be much faster here than anywhere else,” said Robert Wicke, CEO of Halo Labs.

About Halo Labs

Halo Labs is a venture-backed scientific instrumentation company that commercializes high-throughput biopharmaceutical quality control tools for particle analysis using the latest optics and image processing technologies.  Our core mission has been to provide researchers with unprecedented insights into the particles present in their processes by leveraging our core scientific competency: novel imaging optics and software. Today, we dedicate our collective experience and novel technology to empower formulation researchers to learn more about the stability and quality of their drugs faster and with more accuracy than ever before.  For more information, please visit www.halolabs.com

Contact
John Proctor, Ph.D.
VP of Marketing
info@halolabs.com